Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05487404 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels
A Phase 1 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT05487404 is a Phase 1 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT05487404, a Phase 1 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
A Double-Blind Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels
Interventions
- DRUG Placebo
- DRUG ADX-629
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2022-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05487404
The ClinicalTrials.gov registry entry for NCT05487404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05487404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05487404 about?
NCT05487404 is a clinical study titled "A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels". A Double-Blind Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels
What is the current status of trial NCT05487404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2021-11-15. Estimated completion is 2022-05-29.
What interventions are being tested in trial NCT05487404?
The interventions under investigation include: Placebo (DRUG), ADX-629 (DRUG).
Who is sponsoring clinical trial NCT05487404?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.